无症状或亚临床感染的COVID-19儿童临床特征分析

目的 分析无症状或亚临床感染的2019冠状病毒病（COVID-19）儿童的临床特点。方法 回顾性分析53例无症状或亚临床感染的COVID-19患儿的临床资料，总结其流行病学史、临床分型、合并感染情况、鼻咽拭子新型冠状病毒（SARS-CoV-2）核酸转阴时间、实验室检查结果、住院天数及治疗转归。结果 无症状或亚临床感染的COVID-19患儿占呼吸内科COVID-19病房住院患儿的30.5%（53/174），均呈家庭聚集性发病，其中无症状感染者35例（66%），亚临床感染者18例（34%）。17例（32%）患儿存在支原体感染。53例患儿鼻咽拭子SARS-CoV-2核酸转阴平均时间为9±4 d，实验室指标多在正常范围内，住院平均时间为11±4 d。18例亚临床感染患儿肺部CT表现为磨玻璃影、条索影、斑片状影，病变相对局限。结论 呼吸内科COVID-19病房住院患儿中无症状或亚临床感染的COVID-19患儿所占比例较高，其传播风险应引起重视，提高有效防护是儿童防御的关键。     

上海380例家庭聚集性感染Omicron变异株的儿童及其家属临床特征分析（英文翻译）

目的 分析亲子病房收治模式下,家庭聚集性感染Omicron变异株的儿童及其家属的临床特点及转归。 方法 回顾性收集上海市第六人民医院新型冠状病毒肺炎（coronavirus disease 2019,COVID-19）定点医院于2022年4月8日至5月10日收治确诊的感染Omicron变异株患儿190例及其家属190例的临床资料,进行分析总结。 结果 儿童组和成人组均以轻型为主,儿童组轻型比例高于成人组（P<0.05）;2组临床表现均以上呼吸道症状为主,儿童组发热、腹痛腹泻、喘息发生率高于成人组（P<0.05）,鼻塞流涕咳嗽、咽干咽痒咽痛发生率低于成人组（P<0.05）;成人组治疗连花清瘟颗粒/小儿豉翘清热颗粒、中药汤剂、重组人干扰素α2b喷雾剂、止咳化痰药、奈玛特韦/利托那韦片使用率均高于儿童组（P<0.05）;儿童组疫苗接种率（30.5%）较成人组（71.1%）低（P<0.001）,而儿童组严重急性呼吸综合征冠状病毒2（severe acute respiratory syndrome coronavirus 2,SARS-CoV-2）核酸阳性持续时间短于成人组（P<0.05）。2组临床轻型者SARS-CoV-2核酸阳性持续时间短于普通型者（P<0.05）。2组有基础疾病者SARS-CoV-2核酸阳性持续时间长于无基础疾病者（P<0.05）。 结论 家庭聚集性Omicron变异株感染儿童和成人的临床分型均以轻型为主。尽管儿童疫苗接种率较低,但在亲子病房收治模式中,疾病恢复较快,SARS-CoV-2核酸阳性持续时间短于成人。     

Two case reports and a literature review of typical GBS and rare GBS variants associated with COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019, and is the infectious agent that caused the coronavirus disease 2019 (COVID-19) pandemic. Although respiratory and gastrointestinal manifestations of SARS-CoV-2 are well defined, the spectrum of neurological involvement is less defined. The classic type of Guillain–Barré syndrome (GBS) progresses over days to weeks and has a monophasic course. Areflexia/hyporeflexia and ascending and symmetrical paralysis are observed clinically in patients. It is an autoimmune process that typically leads to the destruction of myelin after infection. There have been numerous reports of adult patients with the coexistence of GBS disease and active COVID-19 illness, but this number is lacking for children. In this study, we present a literature review of the etiological correlation between SARS-CoV-2 and GBS and describe the cases of two pediatric patients with acute monophasic Guillain–Barré syndrome (GBS) during active COVID-19 infection.     

Short-term persistent symptoms in preschool children with mild/common coronavirus disease 2019 caused by Omicron variant infection after discharge: a follow-up study北大核心CSCD

目的探讨学龄前儿童感染严重急性呼吸综合征冠状病毒-2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)Omicron变异株后的相关持续症状,为制订感染后的随访计划,减少和预防患儿感染后的相关症状提供依据。方法以2022年4月13日—5月8日由上海市仁济医院南院儿科病房出院的0~5岁Omicron BA.2感染的患儿为研究对象,收集人口学及临床资料,并以连续2次、间隔时间超过24 h的SARS-CoV-2核酸转阴时间为随访起点,其转阴后的4~5周为随访截点,对主要带养人进行电话随访,了解患儿出院后相关持续症状。结果符合纳入条件的103例患儿中,男孩61例,女孩42例,中位年龄为18个月。主要带养家长已接种2针及以上新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)疫苗的比例为64.1%(66/103)。患儿最常见的症状为发热(98.1%,101/103),其次是咳嗽/咳痰(63.1%,65/103)、胃肠道问题(37.9%,39/103)、食欲下降(30.1%,31/103)、乏力(27.2%,28/103)、鼻塞/流涕(16.5%,17/103)等。出院1个月时随访报告44例(42.7%)至少有1种持续症状,包括呼吸道相关症状(14例,13.6%)、胃肠道问题(19例,18.4%)等。主要带养人接种2针及以上COVID-19疫苗的患儿SARS-CoV-2核酸转阴时间较家长未接种或接种1针的患儿核酸转阴时间缩短(P<0.05),但2组患儿存在至少1种持续症状的比例差异无统计学意义(P>0.05)。结论近半数SARSCoV-2 Omicron变异株感染学龄前儿童出院后存在持续相关症状,多为胃肠道症状和呼吸道症状,但大部分症状轻微,需持续随访关注其转归情况。主要带养人COVID-19疫苗接种对儿童可起到一定的保护作用。     

轻症COVID-19患儿流行病学和临床特征分析

目的 探讨轻症2019-冠状病毒病(coronavirus disease 2019,COVID-19)患儿的流行病学和临床特征.方法 以2020年2月5日至3月10日武汉市武昌方舱医院确诊的轻症COVID-19儿童患者为研究对象,收集患儿住院期间和隔离期随访的临床、实验室、肺部影像学资料.该研究为回顾性、单中心系列病...     

201例儿童新型冠状病毒Omicron变异株感染的临床特征分析

目的 探讨新型冠状病毒Omicron变异株感染患儿的临床特征。 方法 回顾性收集2022年3月14日—4月7日泉州市第一医院201例确诊为新型冠状病毒Omicron变异株感染的住院患儿的临床资料。其中无症状感染34例,有症状感染167例。比较两组患儿临床特征、辅助检查结果及转归。 结果 201例患儿中,161例（80.1%）有新型冠状病毒感染患者接触史,132例（65.7%）有新型冠状病毒感染疫苗接种史。167例有症状感染患儿中,轻型151例,普通型16例,无重症感染及死亡病例。101例进行胸部CT检查的患儿中,16例有磨玻璃样改变,20例有结节状或条索影改变。201例患儿新型冠状病毒核酸转阴时间为（14±4）d,其中有症状感染组核酸转阴时间长于无症状感染组［（15±4）d vs（11±4）d,P<0.05］。接种1剂或2剂新型冠状病毒感染疫苗组IgG检出阳性率高于未接种疫苗组（P<0.05）。有症状感染组血淋巴细胞计数增高比例低于无症状感染组（P<0.05）;有症状感染组白细胞介素-6水平增高、血纤维蛋白原增高及D-二聚体增高患儿比例均高于无症状感染组（均P<0.05）。 结论 感染Omicron变异株的患儿多有临床症状,但临床症状一般较轻。有症状感染患儿多伴有血淋巴细胞计数降低或正常,以及白细胞介素-6、纤维蛋白原、D-二聚体升高表现,且核酸转阴时间较长,部分患儿胸部CT呈磨玻璃样改变。     

Description of a national,multi-center registry of patients with sickle cell disease and SARS-CoV-2 infection: Data from the Pediatric COVID-19 United States Registry

Children with sickle cell disease (SCD) are at risk of complications from viral infections, including SARS-CoV-2. We present the clinical characteristics and outcomes of pediatric patients with SCD from the Pediatric COVID-19 United States Registry who developed acute COVID-19 due to SARS-CoV-2 infection (n = 259) or multisystem inflammatory syndrome in children (MIS-C; n = 4). Nearly half of hospitalized children with SCD and SARS-CoV-2 infection required supplemental oxygen, though children with SCD had fewer intensive care (ICU) admissions compared to the general pediatric and immunocompromised populations. All registry patients with both SCD and MIS-C required ICU admission. Children with SCD are at risk of severe disease with SARS-CoV-2 infection, highlighting the importance of vaccination in this vulnerable population.     

Trends in Pediatric Viral Symptoms,Influenza Testing,and SARS-CoV-2 Testing From a Statewide Electronic Health Record Consortium,January 2017 to July 2021

ObjectiveThe heterogeneous implementation and uptake of nonpharmaceutical interventions (NPIs) during the coronavirus disease 2019 (COVID-19) pandemic amplified the need for locally responsive disease surveillance mechanisms. Using data from a newly developed statewide electronic health record (EHR) consortium in Minnesota, we sought to characterize trends in pediatric viral symptoms, influenza testing, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing.MethodsWe conducted a serial cross-sectional analysis of EHR data from 1/1/2017 to 7/30/2021 across 8 large health systems in Minnesota. We included patients ≤18 years of age with any SARS-CoV-2 test, influenza test, or documented diagnostic code which met our viral symptom definition. We plotted week-by-week trends in viral symptoms, SARS-CoV-2 and influenza testing, and test positivity, stratified between children (0–11 years) and adolescents (12–18 years).ResultsWe identified 1,079,924 patients ≤18 years of age with viral symptoms or testing; 880,669 (81.5%) were children ≤11 years. Influenza testing and influenza test positivity remained well below historical averages from March 2020 through mid-May 2021. Peaks in viral symptoms during this time were concomitant with peaks in SARS-CoV-2 testing and test positivity, whereas influenza testing and test positivity remained stagnant. Influenza test positivity rates increased substantively among children from May through July 2021.ConclusionsViral illness and influenza testing among pediatric patients were below historical averages throughout the COVID-19 pandemic. Ongoing increases in influenza test positivity may merit clinical and public health awareness and intervention. Future NPI policies can be better targeted with insights from collaborative EHR-based surveillance, which enhances real-time, locally sensitive measurement of disease outbreaks.     

Clinical characteristics of COVID-19 infection in polyhandicapped persons in France

AimLittle is known about the clinical profile of COVID-19 infection in polyhandicapped persons. This study aimed to describe the characteristics of this infection among individuals with polyhandicap.MethodThis was a retrospective observational study. Polyhandicap was defined by the combination of motor deficiency, profound mental retardation, and age at onset of cerebral lesion younger than 6 years. A positive COVID-19 status was considered for patients with a positive COVID-19 laboratory test result, or patients presenting with compatible symptoms and living in an institution or at home with other patients or relatives who had laboratory-confirmed COVID-19 infection. Data collection included sociodemographic data, clinical and paraclinical characteristics, as well as the management and treatment for COVID-19 infection.ResultsWe collected 98 cases, with a sex ratio of 0.98 and a mean age of 38.5 years (3 months to 73 years). COVID-19 infection was paucisymptomatic in 46% of patients, 20.6% of patients presented with dyspnea, while the most frequent extra-respiratory symptoms were digestive (26.5%) and neurological changes (24.5%); 18 patients required hospital admission, four adults died. The mean duration of infection was longer for adults than for children, and the proportion of taste and smell disorders was higher in older patients.ConclusionThese findings suggest that PLH persons often develop paucisymptomatic forms of COVID-19 infection, although they may also experience severe outcomes, including death. Clinicians should be aware that COVID-19 symptoms in PLH persons are often extra-respiratory signs, mostly digestive and neurologic, which may help in the earlier identification of COVID-19 infection in this particular population of patients.     

江西地区23例18岁以下儿童2019冠状病毒病临床分析

目的 研究18岁以下儿童2019冠状病毒病（COVID-19）的临床特征。方法 回顾性分析江西地区2020年1月21日至2020年2月29日确诊的23例儿童COVID-19的临床资料（患儿年龄为3个月至17岁8个月）。结果 23例COVID-19患儿中，17例为家庭聚集性发病；无症状感染3例（13%），轻型6例（26%），普通型14例（61%）。发热16例（70%），咳嗽11例（48%），发热伴咳嗽8例（35%），肺部湿啰音8例（35%）。从发病或首次新型冠状病毒SARS-CoV-2核酸阳性至核酸转阴时间为6~24 d（中位数12 d）。3例白细胞总数降低，2例淋巴细胞下降，2例C反应蛋白增高，2例D-二聚体增高。12例肺部CT异常，其中肺内片状磨玻璃影9例。23例均应用了抗病毒治疗，均治愈出院。结论 18岁以下儿童COVID-19多为家庭聚集性发病，临床表现、实验室检查无特异性，症状较轻，预后较好。流行病学史在18岁以下儿童COVID-19诊断中非常重要。     

杭州市19例新型冠状病毒Omicron变异株感染儿童的临床特征

目的 探讨儿童新型冠状病毒Omicron变异株感染者的临床特征,为临床诊疗提供参考。方法 回顾性分析杭州市19例2022年1月28日至3月3日确诊为新型冠状病毒Omicron变异株感染儿童的临床资料。结果 19例患儿中,男性7例(37%),女性12例(63%);年龄0.5～16.0岁,中位年龄为2岁1个月,以婴幼儿(≤3岁)多见(53%)。未接种新型冠状病毒疫苗者11例(58%),接种者8例(42%)。3例(16%)有基础疾病史。19例患儿均有明确的新型冠状病毒感染者的密切接触史,其中母婴看护机构聚集性发病10例(53%)。临床表现为轻型13例(68%),普通型6例(32%),无重型病例。最常见症状为咳嗽(100%)和发热(63%)。患儿外周血白细胞计数(84%)及淋巴细胞计数多正常(68%)。患儿的血小板计数、降钙素原、肝功能指标(丙氨酸氨基转移酶、天冬氨酸氨基转移酶)、肾功能指标(肌酐、尿素)无明显异常。6例(32%)胸部CT有明显肺炎征象。19例患儿均给予对症治疗,12例(63%)雾化吸入干扰素α。所有患儿治愈出院。结论 儿童Omicron变异株感染病例以婴幼儿多见,症状轻,预后...     

冠状病毒感染孕产妇及其分娩新生儿临床结局的系统综述

目的比较严重急性呼吸综合征冠状病毒1(SARS-CoV-1)、中东呼吸综合征病毒（MERS-CoV）及严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染孕妇的妊娠结局及对新生儿的影响,为指导SARS-CoV-2感染的防治提供证据。方法纳入核酸检测确诊冠状病毒（SARS、MERS和 COVID-19）感染的孕产妇分娩的新生儿,系统检索SARS、MERS和COVID-19孕妇的妊娠结局及新生儿文献,在Pubmed、中国生物医学文献数据库（CBM）和中国知网数据库（CNKI）检索,并在WHO COVID-19文献数据库和纳入文献的参考文献中进行补充检索,检索起止时间：2000年1月1日至2020年3月9日。分别通过阅读摘要和全文进行文献筛选,排除诊断试剂、分子诊断等方面文献。文献提取和评价均得到临床指南制作和评价中心专业人员的培训和审核,并对文献行偏倚风险评价。结果共纳入42例确诊冠状病毒感染的孕产妇和36例活产新生儿。其中SARS-CoV-1感染孕产妇13例,死亡3例 (23%),存活10例中4例在孕早期发生自然流产 (40%),其余6例分娩活产新生儿6例 (早产4例,足月2例),均未发生SARS-CoV-1感染;确诊MERS-CoV感染孕产妇2例,存活2例共分娩活产新生儿2例（早产、足月各1例）, 均未发生MERS-CoV感染;确诊SARS-CoV-2感染孕产妇27例,无产妇死亡病例,分娩活产新生儿28例 (双胞胎1例),咽拭子SARS-CoV-2核酸检测阳性新生儿3例,1例重型病例（先天性房间隔缺损）、2例轻型病例,生后新生儿与家人均有密切接触史,无证据显示胎盘垂直传播,均未行亲自母乳喂养,均治愈出院。结论文献报道不够充分的SARS-CoV-1和MERS-CoV感染孕产妇及其新生儿流行病学和临床特征,对SARS-CoV-2感染孕产妇及其新生儿感染预防、诊断和治疗仍有一定的参考价值。尽管文献存在高偏倚风险,但SARS-CoV-2感染晚期孕产妇及其新生儿出院时的结局是好的。     

Prophylaxis with urokinase in pediatric oncology patients with central venous catheters

This study evaluated the effects of urokinase in the prevention of central venous catheter (CVC)-related complications in children with malignancy. Fifteen patients with 16 CVCs (study group A) received an intraluminal application of urokinase (10,000 IU in each catheter lumen for 4 h) once a week. They were monitored prospectively with quantitative blood cultures and ultrasonography (color Doppler ultrasound of the great veins and echocardiography). The rate of complications was compared with that of 15 children with 19 CVCs without thromboprophylaxis, treated the previous year (control group B). The authors found a significantly lower incidence of CVC dysfunction (3/16 versus 13/19), no major thrombosis, fewer CVC-related bacteremias (2/16 versus 8/19), and a higher salvage of CVCs (1/16 versus 5/19 CVC removals due to persistent bacteremia) in the thromboprophylaxis group. Asymptomatic thrombosis rate was also lower (7/16 cases in group A versus 9/11 in group B when sonography was performed). No hemorrhagic complications were noted. Thromboprophylaxis with urokinase seems a safe and effective measure for reducing the rate of CVC-related complications.     

儿童COVID-19合并高血压2例

该文报道2例新型冠状病毒肺炎（COVID-19）合并高血压基础疾病患儿的诊疗经过。病例1为13岁3月龄男性患儿，以发热、干咳为主要表现，胸部CT提示左下肺叶磨玻璃影，咽拭子新型冠状病毒（SARS-CoV-2）核酸检测阳性；病例2为13岁8月龄男性患儿，无临床症状，胸部CT无异常，咽拭子SARS-CoV-2核酸检测阳性。两者均为家族聚集性发病，均有高血压家族史，且体质肥胖，住院期间连续多次监测静息状态下血压高于同龄儿童正常值95%参考区间，分别予钙通道阻滞剂及β受体阻滞剂，血压控制可，临床痊愈出院。该文病例提示应重视疫情期间对有高血压等心血管基础疾病的COVID-19患儿的综合管理。     

接种新型冠状病毒灭活疫苗后感染Delta变异株的新型冠状病毒肺炎患儿临床特征分析

目的 通过比较接种/未接种新型冠状病毒灭活疫苗（简称新冠疫苗）后感染新型冠状病毒Delta变异株的新型冠状病毒肺炎（coronavirus disease 2019,COVID-19）患儿的临床特征,为儿童COVID-19的临床诊疗提供参考。方法 将2021年11月3日至12月17日河南省定点救治医院收治的接种新冠疫苗后感染新型冠状病毒Delta变异株的COVID-19患儿11例纳入接种疫苗组,同期住院的未接种新冠疫苗感染新型冠状病毒Delta变异株的COVID-19患儿31例纳入未接种疫苗组,回顾性收集两组患儿的流行病学、临床特征及实验室检查资料进行比较。结果 两组患儿性别构成和疾病分型比较差异均无统计学意义（P>0.05）。咳嗽、咳痰、发热等临床症状发生率在两组间比较差异均无统计学意义（P>0.05）。白细胞计数、淋巴细胞百分比、丙氨酸氨基转移酶水平、血肌酐水平升高发生率在两组间比较差异均无统计学意义（P>0.05）。接种疫苗组患儿天冬氨酸氨基转移酶、乳酸脱氢酶、肌酸激酶同工酶水平明显低于未接种疫苗组（P<0.05）。两组患儿C反应蛋白、降钙素原水平增高发生...     

Covid-19 in children: A brief overview after three months experience

Severe Acute Respiratory Syndrome – Coronavirus – 2 (SARS-CoV-2) and its related Coronavirus Disease – 19 (COVID-19) has become a health emergency worldwide. The medical community has been concerned since the beginning of the outbreak about the potential impact of COVID-19 in children, especially in those with underlying chronic diseases. Fortunately, COVID-19 has been reported to be less severe in children than in adults. However, epidemiologic and clinical data are scarce. Children show unique features of SARS-CoV-2 involvement that may account for the low rate of infection and death in this age group. The purpose of this review is to summarize the most relevant evidence of COVID-19 in children highlighting similarities and differences with adults.     

Cystic fibrosis as a risk factor for recurrent venous thrombosis at a pediatric tertiary care hospital

OBJECTIVE: To evaluate risk factors for recurrent thrombosis in pediatric patients. STUDY DESIGN: This prospective observational cohort study enrolled 120 patients with acute venous thromboembolism from January 2003 to April 2005. Data collection included medical and family history, radiologic and laboratory studies, therapy, and follow-up. RESULTS: The overall prevalence of recurrent thrombosis in our cohort was 19/120 (15.8%). Patients with recurrence were older, with a median age of 14.8 years (range 2 weeks-23.6 years), compared with 10.1 years (range newborn 23.4 years) in patients without recurrence (P = .03). Six of the 19 patients with recurrent thrombosis had cystic fibrosis (CF), compared with 0/101 without recurrence (P < .001). Five of these 6 patients were colonized with Burkholderia cepacia in their sputum. Central venous catheters were associated with most, but not all, of the thromboses in patients with CF. CONCLUSIONS: In this study, patients with CF had a high risk of recurrent venous thrombosis, as well as a high prevalence of colonization with B cepacia. The cause of this risk has not been defined. This observation may have important implications for thromboprophylaxis, particularly in the setting of central venous catheters.     

Characteristics and predictors of outcomes of critically Ill children with SARS-CoV-2 infection - the PICU experience

ObjectiveTo describe the clinical characteristics, laboratory parameters, treatment, and predictors of an unfavorable outcome of critically ill children with SARS-CoV-2 infection.MethodThis was a prospective observational study performed in a pediatric intensive care unit (PICU) of a tertiary care COVID referral hospital among critically ill children in the age group 1 month - 12 years admitted due to SARS-CoV-2 infection from June to December 2020. Demographic, clinical profile, pSOFA and PRISM III scores, laboratory parameters, treatment, and outcomes of the patients were recorded. Children who had a prolonged PICU stay (>14 days) or died were compared with those who were discharged from PICU within 14 days to assess predictors of unfavorable outcomes.ResultsPICU admission rate among hospitalized SARS-CoV-2 infected children was 22.1% (92/416). Infants comprised the majority of the ICU population. Invasive mechanical ventilation and inotropic support were required for 28.3% and 37% of patients, respectively. Remdesivir, IVIg, and steroids were administered to 15.2%, 26.1%, and 54.3% of the subjects, respectively. The mortality rate was 7.6 %. MIS-C patients were older, less comorbid, and required less ventilator support but more inotrope support than acute severe COVID-19 patients. Predictors of unfavorable outcomes were age < 1 year, fever duration > 5 days, respiratory distress, shock, comorbidity, elevated CRP (> 50 mg/L), procalcitonin (> 6 ng/L), D-dimer (> 6 µg/L) and arterial lactate (> 2 mmol/L).ConclusionCritically ill children with unfavorable outcomes were predominantly infants, comorbid, prolonged fever, respiratory distress, shock and elevated inflammatory markers, D-dimer and lactate. These factors may be useful for watchful monitoring and early intervention.     

新生儿重型新型冠状病毒肺炎转运治疗1例病例报告

目的探讨新生儿新型冠状病毒肺炎（COVID-19）的传播能力、转运安全性、诊断和治疗。方法分析1例COVID-19新生儿的流行病学史、转运过程和治疗转归。结果患儿男,22日龄,因“间断发热17 d”于2020年2月22日由外院120负压转运车转入郑州大学附属儿童医院（我院）。患儿父母（孕37+3周）1月22日从武汉回河南省外公家待产,母亲、父亲、外公、外婆相继出现发热等症状,1月31日母亲剖宫产分娩,父母和新生儿住同一间母婴病房,2月1日母确诊COVID-19,父亲、外公和外婆相继确诊COVID-19。2月5日患儿发热,次日确诊COVID-19,胸部X线片可见弥漫性多发实变影,当地医院隔离治疗17 d仍需鼻氧管吸氧,体温37.5℃,医护人员在三级防护下120负压转运车4.5 h转运至我院,暖箱保暖,人工喂养,鼻氧管吸氧,FiO2 40%,流量1 L·min-1,干扰素α-1b喷口鼻腔。床旁心脏彩超示房间隔缺损（6.9 mm）,血NT-proBNP 1950 pg·mL-1,有心功能不全的表现,予限制液体入量。患儿2月28日咽拭子核酸检测阴性,3月1日咽拭子和粪便SARS-CoV-2核酸检测均为阴性,胸部CT见右肺下叶片影明显吸收,3月6日出院。结论新生儿重型COVID-19病例在病情需要时在有效的安全防护下长途转运是可能的。本病例不支持母婴垂直传播,未引起成人感染。合并有心脏基础疾病时,应注意液体管理。